Sonoma Pharmaceuticals announced the nationwide rollout of its advanced hypochlorous acid–based burn relief hydrogel in CVS and Walmart stores, marking the company’s first entry into a major U.S. retail pharmacy channel. The hydrogel is formulated to soothe minor burns and skin irritations, leveraging Sonoma’s proprietary stabilized HOCl technology for rapid antimicrobial action.
The launch builds on Sonoma’s prior consumer success, notably the diaper rash hydrogel introduced in 2025, and signals a strategic shift toward mainstream over‑the‑counter products. CEO Amy Trombly highlighted that the move expands the company’s distribution beyond prescription dermatology and mail‑order programs, positioning the brand for broader consumer reach.
Financially, Sonoma reported 27% revenue growth to $17.7 million over the last twelve months, supported by the new product line, and a gross profit margin of 38%. The company’s market capitalization hovered around $4.2 million in late March, while the stock has declined roughly 30% year‑to‑date. The hydrogel launch is expected to contribute to continued top‑line momentum and margin stability as the company scales its HOCl portfolio.
Market reaction to the announcement has been modest; the stock rose 6.25% over the past week to $2.55, but this movement is not directly attributable to the burn relief hydrogel launch. Investors appear to be weighing the company’s broader growth prospects against its current valuation and YTD decline.
In the competitive landscape, Sonoma faces peers such as InMed Pharmaceuticals and CordovaCann, but its unique HOCl technology differentiates it in wound care and dermatology. The retail expansion is a key step in capturing a larger share of the consumer market, potentially accelerating future product introductions and reinforcing the company’s position as a specialist in antimicrobial solutions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.